CytoMed Therapeutics Issues Press Release
Ticker: GDTC · Form: 6-K · Filed: Jul 21, 2025 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, filing
TL;DR
CytoMed Therapeutics dropped a press release on 7/21/25, details TBD.
AI Summary
On July 21, 2025, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of this press release.
Why It Matters
This filing indicates a communication from CytoMed Therapeutics, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing a press release without providing specific material details.
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Filer of the 6-K report
- July 21, 2025 (date) — Date of press release issuance
- 001-41677 (other) — Commission File Number
FAQ
What is the subject of the press release issued by CytoMed Therapeutics on July 21, 2025?
The filing states that CytoMed Therapeutics Limited issued a press release on July 21, 2025, but does not specify its subject matter.
What is the Commission File Number for CytoMed Therapeutics Limited?
The Commission File Number for CytoMed Therapeutics Limited is 001-41677.
What is the principal executive office address for CytoMed Therapeutics Limited?
The principal executive office address is 1 Commonwealth Lane #08-22, Singapore 149544.
Is CytoMed Therapeutics Limited required to file annual reports on Form 20-F or 40-F?
Yes, CytoMed Therapeutics Limited is indicated to file annual reports under cover of Form 20-F.
When was the company formerly known as CytoMed Therapeutics Pte. Ltd.?
The company's former name was CytoMed Therapeutics Pte. Ltd., and the date of the name change was July 16, 2021.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 21, 2025 regarding CytoMed Therapeutics Ltd (GDTC).